Sandoz

Sandoz, spun off from Novartis in October 2023, is a global champion in the off-patent pharmaceuticals market, dedicated to its social mission of expanding access to medicine. It achieves this through a dual-pillar strategy: a broad portfolio of generic drugs and a rapidly growing, scientifically advanced biosimilars franchise. As an independent public entity, Sandoz is now positioned to accelerate growth, optimize its capital structure, and directly capitalize on the significant long-term tailwinds in both the generics and biosimilars sectors worldwide.

An integrated capability suite combining advanced analytical characterization and bioprocessing for biosimilars with sophisticated formulation science and specialized manufacturing for complex generics, supported by a global internal production network.

Sandoz competes with large global generics firms (Teva, Viatris) and specialized biosimilar players (Amgen, Pfizer, Celltrion). Its key advantages are its standalone focus, fully integrated development-to-commercial model, strong global brand, and proven launch capabilities in complex products.